An ethics panel at the Institute for Biomedical Research and Innovation in Japan has given the green light for a clinical trial of induced pluripotent stem cells in the treatment of age-related macular degeneration. If Japan's Health Ministry approves the six-patient trial, it could begin this fiscal year.

Related Summaries